Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9653.9160
Address
Suite 1 Level 9 432 St Kilda Road Melbourne, Victoria (VIC) 3004
Description
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. Its proprietary apps, software, and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes, and reduce healthcare expenditures. The firm operates through the Australia and Israel segments. The Australia segment includes research, development, and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment refers to the research, development and, commercialization of medical devices, and the production of mobile health applications in Israel. The company was founded by Noam Gavriely in 1987 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.1
Trade Value (12mth)
AU$10,684.00
1 week
4.17%
1 month
-7.41%
YTD
158.62%
1 year
134.37%
All time high
6.57
EPS 3 yr Growth
-55.70%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-365.10%
ROIC
-392.00%
Interest Coverage
-116.70
Quick Ratio
0.40
Shares on Issue (Fully Dilluted)
1131m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 December 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
05 December 24 |
2024 EGM - Letter to Shareholders & Proxy Form
×
2024 EGM - Letter to Shareholders & Proxy Form |
29 November 24 |
Application for quotation of securities - RSH
×
Application for quotation of securities - RSH |
28 November 24 |
Investor Presentation
×
Investor Presentation |
26 November 24 |
Respiri Signs Binding Purchase Agreement with Orb Health
×
Respiri Signs Binding Purchase Agreement with Orb Health |
26 November 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
26 November 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
22 November 24 |
Trading Halt
×
Trading Halt |
20 November 24 |
Results of Meeting
×
Results of Meeting |
06 November 24 |
November 2024 Investor Presentation
×
November 2024 Investor Presentation |
06 November 24 |
Addendum to Notice of AGM
×
Addendum to Notice of AGM |
05 November 24 |
Positive changes to RPM reimbursement criteria
×
Positive changes to RPM reimbursement criteria |
31 October 24 |
Respiri Market Update Presentation
×
Respiri Market Update Presentation |
24 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
21 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
21 October 24 |
2024 AGM - Letter to Shareholders & Proxy Form
×
2024 AGM - Letter to Shareholders & Proxy Form |
15 October 24 |
Respiri Secures A$1.6 Million Strategic Investment
×
Respiri Secures A$1.6 Million Strategic Investment |
15 October 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
11 October 24 |
Trading Halt
×
Trading Halt |
07 October 24 |
Notification of cessation of securities - RSH
×
Notification of cessation of securities - RSH |
07 October 24 |
Change of Director's Interest Notices X2
×
Change of Director's Interest Notices X2 |
04 October 24 |
RSH Programs Record Significant Healthcare Cost Reduction
×
RSH Programs Record Significant Healthcare Cost Reduction |
03 October 24 |
Application for quotation of securities - RSH
×
Application for quotation of securities - RSH |
02 October 24 |
Date of Annual General Meeting
×
Date of Annual General Meeting |
23 September 24 |
RSH secures 1st agreements with Skilled Nursing Facilities
×
RSH secures 1st agreements with Skilled Nursing Facilities |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.